Clinical trial
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With…
NCT00002767 · GlaxoSmithKline, Industry · Unknown status
Key facts
| NCT number | NCT00002767 |
|---|---|
| Title | Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | Detox-B adjuvant, recombinant interferon alfa |
| Enrollment | 300 |
| Start date | Jan 1, 1996 |
| First posted | Sep 2, 2004 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: